ACACIA RESEARCH CORP annual report, FY2019

Business context and reporting period

Acacia Research Corporation’s Form 10-K covers the fiscal year ended December 31, 2019. The company invests in intellectual property and monetizes patent rights through licensing and, when needed, litigation. It reported 17 full-time employees and operates as a single patent licensing and enforcement segment.

Financial performance and liquidity

Operating margin was approximately negative 208% in 2019, calculated from reported revenue and operating loss. Cash, cash equivalents and trading securities totaled $168.3 million at year-end; working capital was $160.1 million. An additional $35.0 million of cash was held in long-term restricted escrow under the Starboard transaction, subject to release conditions. Management said cash and anticipated operating cash flows should meet requirements through at least March 2021. The filing reports no off-balance-sheet financing arrangements and no conventional debt balance at year-end; preferred-stock and warrant-related liabilities were recorded.

Investing cash outflow was $68.1 million, principally reflecting net purchases of trading securities; financing cash inflow was $33.9 million, mainly from the Starboard preferred-stock issuance. The company raised $35.0 million gross, or $33.8 million net of issuance costs. The cash-flow statement reports ending cash and restricted cash of $92.4 million, distinct from the broader cash-and-trading-securities total.

Material changes versus 2018

• Revenue declined 91%, primarily reflecting fewer and lower-value new agreements: seven agreements were executed in 2019 versus 12 in 2018. Six licensing programs generated revenue versus eight.
• Operating costs and expenses fell 78% to $34.7 million. Lower royalties and contingent legal fees, reduced general and administrative expense, and lower patent amortization contributed. The 2018 comparison included $28.2 million of patent impairments and $8.3 million of accelerated amortization; there were no patent impairment charges in 2019.
• Net loss narrowed substantially, chiefly because 2018 included a $59.1 million unrealized loss on the Veritone investment. In 2019, Acacia recorded a $9.9 million unrealized gain, offset in part by a $9.2 million realized loss on Veritone share sales and an $8.2 million impairment of Miso Robotics.
• Acacia acquired five patent portfolios in 2019, compared with none in 2018. Its remaining patent assets had a weighted-average estimated useful life of four years.

Outlook, risks and unusual items

• No numerical revenue or earnings guidance was provided. Management described efforts to monetize existing portfolios, rebuild the pipeline and pursue opportunities that complement the legacy IP business. Three patent infringement cases had trial dates scheduled within 12 months of the report, but timing and outcomes are uncertain.
• Starboard’s November 2019 investment included 350,000 shares of Series A preferred stock and warrants for up to five million common shares. The preferred stock carries a 3% cumulative annual dividend, with a potential step-up to 8% after an approved investment; it also has conversion, redemption and liquidation-preference rights. A $35.0 million escrow restriction and governance rights are material transaction features.
• Subsequent to year-end, stockholders approved expanded common-share authorization and related conversion and warrant issuances. On February 25, 2020, Acacia issued Series B warrants for up to 100 million shares for $4.6 million; exercise terms include cash exercise at $5.25 per share or cancellation of senior secured notes at $3.65 per share. The company may issue senior secured notes under the transaction terms.
• Revenue is inherently uneven and concentrated: three licensees generated 43%, 22% and 15% of 2019 revenue. Patent litigation entails uncertain outcomes, potentially lengthy proceedings and possible sanctions or fee awards. The Celltrace arbitration remained pending, with Acacia contesting the claims. Accrued litigation liabilities were $6.2 million.
• The filing discusses COVID-19 as a potential material risk to Acacia, licensees and business partners. Acacia reported a full valuation allowance against net deferred tax assets and warned that ownership changes could limit use of tax attributes. A California tax audit was ongoing; proposed adjustments for 2011 and 2012 were described as not material if expensed.
• Acacia restated the presentation of cash flows in its 2019 interim reports, moving trading-security cash flows from operating to investing activities; the reclassification did not change the reported change in cash. Management and the auditor reported effective internal controls, and the auditor issued unqualified opinions on the financial statements and internal controls.

Investor facts to verify

• Whether the five newly acquired portfolios and broader pipeline can generate replacement licensing revenue after the steep 2019 decline.
• Availability and permitted use of cash, particularly the $35.0 million restricted escrow, and the company’s liquidity forecast against ongoing legal and operating costs.
• Potential dilution, dividends, redemption obligations and governance effects of the Series A preferred stock and Series A and Series B warrants, including any senior secured note issuance.
• Progress and financial exposure from patent litigation, the pending Celltrace arbitration and the accrued litigation liabilities.
• Revenue concentration, the fair value and remaining exposure of investment holdings, and realizability of tax attributes subject to ownership-change limits.